CA-ARMIS
Armis, the asset intelligence cybersecurity company, today announced that it has been named a leader by analyst group Quadrant Knowledge Solutions in three 2023 SPARK Matrix™ reports for Q4 2023. The reports: SPARK Matrix™: Vulnerability Management, Q4 2023, SPARK Matrix™: Operational Technology (OT) Security, Q4 2023, and SPARK Matrix™: Connected Medical Device Security Solutions, Q4 2023, place three Armis Centrix™ solutions as a Technology Leader with significant customer impact in the areas of Vulnerability Management, Operational Technology Security and Connected Medical Device Security.
“Our Leader position in these three reports is a testament to our commitment to innovation and customer success, and helping organizations see, protect and manage their entire attack surface in real-time,” said Dana Gilboa, Chief Product Officer of Armis. “We are extremely proud that Armis is positioned as a Leader on both the Technology Leader axis and the Customer Impact axis for all three reports. We also want to extend a sincere thank you to the Armis customers who took the time to provide feedback on Armis to Quadrant Knowledge Solutions.”
The SPARK Matrix™ reports analyzed three of Armis’ four core solutions: Vulnerability Management, OT/IoT Security, and Medical Device Security, which are all built on Armis Centrix™, the Armis cyber exposure management platform. Powered by the Armis AI-driven Asset Intelligence Engine, Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively identifies all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.
SPARK Matrix™ reports analyze the vendor landscape of a technology category and vendor product capabilities. Vendors are evaluated according to their product offerings, market share and customer satisfaction to help CIOs and CISOs make informed technology decisions.
When evaluating why Armis is a technology leader in each of these three core areas, Quadrant Knowledge Solutions shared in its reports:
- Vulnerability Management - “Armis Centrix™ for Vulnerability Prioritization and Remediation bridges critical coverage gaps unattended by Vulnerability assessment tools with aggregation of details such as ownership and location to create full visibility of the attack surface. Armis Centrix™ for Vulnerability Prioritization and Remediation provides holistic visibility into the user’s overall risk and attack surface. The platform also provides the business context of business-critical assets based on their roles. Armis Centrix™ Asset Vulnerability Prioritization and Remediation helps the organization reduce its attack surface by analyzing attributes of devices and overlaying threat intel as a part of the analysis.”
- Operational Technology Security - “Armis Centrix™ for OT/IoT security enables organizations to see and secure OT/IOT networks and physical assets, ensure uptime, and build an effective & comprehensive security strategy. It is powered by Armis’ AI-driven Asset Intelligence Engine and oversees, secures, protects, and manages a wide range of assets in real-time. The cloud-based platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats, and protects the entire attack surface. Armis for OT/IoT security provides deep visibility to all OT assets as well as to the OT/ICS networks and environment. It allows companies to manage the OT/IT convergence, bridge the IT / OT gap and protect OT networks, monitor connectivity, and track behavior.”
- Connected Medical Device Security - “Armis Centrix™ for Medical Device Security offers features like real-time complete visibility into medical device inventory, information regarding device usage for increasing utilization efficiency, medical device risk assessment based on vulnerabilities, identifying Protected Health Information (PHI) breaches, identifying and remediating threats, and automating security of medical devices. The product is also equipped with an Asset Intelligence Engine with over 20 million device profiles, and the AI-powered Armis Standard Query.”
Learn more about each of these Quadrant Knowledge Solutions reports at the below links:
- SPARK Matrix™: Vulnerability Management, Q4 2023
- SPARK Matrix™: Operational Technology Security, Q4 2023
- SPARK Matrix™: Connected Medical Device Security, Q4 2023
To read our blog, please visit: https://www.armis.com/blog/armis-is-named-a-leader-in-three-2023-quadrant-spark-matrix-reports/
For additional analyst reports sharing insights about Armis Centrix™, go here: https://www.armis.com/resources/?type=analyst-reports
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212672034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
